🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Pfizer Analysts Cut Their Forecasts Following Q3 Results

Published 01/11/2023, 18:29
Updated 01/11/2023, 19:40
© Reuters Pfizer Analysts Cut Their Forecasts Following Q3 Results
PFE
-

Benzinga - by Lisa Levin, Benzinga Editor.

Pfizer Inc (NYSE: PFE) reported a loss for the third quarter on Tuesday.

Pfizer reported a quarterly adjusted EPS loss of 17 cents versus a consensus loss of 32 cents, down from an EPS income of 67 cents in Q2 and $1.78 a year ago. The company reported a 42% slump in Q3 sales to $13.23 billion, down from $22.64 billion a year ago, beating the consensus of $12.72 billion.

Pfizer shares gained 0.2% to trade at $30.61 on Wednesday.

These analysts made changes to their price targets on Pfizer following earnings announcement.

  • Morgan Stanley slashed the price target on Pfizer from $39 to $37. Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating.
  • Barclays lowered the price target on Pfizer from $35 to $34. Barclays analyst Carter Gould maintained an Equal-Weight rating.
Also Check This Out: Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4

Latest Ratings for PFE

DateFirmActionFromTo
Feb 2022Morgan StanleyMaintainsEqual-Weight
Jan 2022Wells FargoMaintainsOverweight
Jan 2022B of A SecuritiesUpgradesNeutralBuy
View More Analyst Ratings for PFE

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.